2025-01-25 11:51:00 :
Dr Reddys Laboratories third quarter 2025 results: Dr Reddys Laboratories announced its third quarter results on January 23, 2025, with revenue increasing by 15.81% year-on-year. Profit increased by 2.38% year-on-year, and profit data reached $Revenue peaked at Rs 1,413.7 crore. $8381.2 Crores.
Compared with the previous quarter, revenue increased by 4.27% and profit increased by 12.58%. However, selling, general and administrative expenses increased by 0.7% month-on-month and 16.53% year-on-year.
This quarter’s operating income increased by 7.27% month-on-month and 9.21% year-on-year. Earnings per share (EPS) is $In the third quarter, it was 16.94, a year-on-year increase of 1.68%.
Dr Reddys Laboratories reported a return of -1.02% last week, a return of -5.93% over the past six months, and a return of -7.14% year-to-date.
Currently, Dr. Reddy’s Laboratories has a market capitalization of $1,07,422.6 billion rupees, a 52-week high $1421.49 and lowest price $1120.
Of the 35 analysts covering the company as of January 25, 2025, 5 have a Strong Sell rating, 8 have a Sell rating, 9 have a Hold rating, 7 have a Buy rating, and 6 have a Buy rating. Named with a Strong Buy rating. As of now, the consensus recommendation is Hold.
Dr Reddy’s Laboratories Financial Status
| period | Q3 (FY2025) | Q2 (FY25) | month-on-month growth | Q3 (FY2024) | year-on-year growth |
|---|---|---|---|---|---|
| total revenue | 8381.2 | 8038.2 | +4.27% | 7236.8 | +15.81% |
| Total Selling/General/Administrative Expenses | 3527.1 | 3502.6 | +0.7% | 3026.7 | +16.53% |
| Depreciation/Amortization | 471.4 | Chapter 397 | +18.74% | 373.5 | +26.21% |
| total operating expenses | 6579.6 | 6358.7 | +3.47% | 5587.2 | +17.76% |
| operating income | 1801.6 | 1679.5 | +7.27% | 1649.6 | +9.21% |
| net income before tax | 1874.3 | 1917.4 | -2.25% | 1829.1 | +2.47% |
| net income | 1413.7 | 1255.7 | +12.58% | 1380.9 | +2.38% |
| Diluted normalized earnings per share | 16.94 | 15.85 | +6.88% | 16.66 | +1.68% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
Follow us On Social Media Twitter/X